Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Leukemia

Volumn 29, Issue 2, 2015, Pages 510-514

  Suzuki, R ^a   Hideshima, T ^a   Mimura, N ^a   Minami, J ^a   Ohguchi, H ^a   Kikuchi, S ^a   Yoshida, Y ^a   Gorgun, G ^a   Cirstea, D ^a   Cottini, F ^a   Jakubikova, J ^a   Tai, Y T ^a   Chauhan, D ^a   Richardson, P G ^a   Munshi, N C ^b   Utsugi, T ^a   Anderson, K C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90 INHIBITOR; TANESPIMYCIN; TAS 116; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; BORONIC ACID DERIVATIVE; HEAT SHOCK PROTEIN 90; HSP90AB1 PROTEIN, HUMAN; HSP90ALPHA PROTEIN, HUMAN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; N-RAS PROTEIN, MOUSE; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; TAS-116;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; EYE TOXICITY; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG SCREENING; HUMAN; METABOLISM; MOUSE; MUTATION; PIGMENT EPITHELIUM; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; BORONIC ACIDS; BORTEZOMIB; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, SCID; MONOMERIC GTP-BINDING PROTEINS; MULTIPLE MYELOMA; MUTATION; NEOPLASM TRANSPLANTATION; PYRAZINES; PYRAZOLES; RETINAL PIGMENT EPITHELIUM;

EID: 84922457791     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.300     Document Type: Article

References (15)

1. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3: 213-217.
2. Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011; 10: 1909-1917.
3. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 2013; 14: e358-e369.
4. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092-1100.
5. Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 in, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011; 17: 6831-6839.
6. Ohkubo S, Muraoka H, Hashimoto A, Ito S, Ito K, Shibata Y et al. TAS-116, a novel, orally bioavailable hsp90α/β selective inhibitor demonstrates highly potent antitumor activity in preclinical models with a favorable pk pro file. Eur J Cancer 2012; 48: 89 (abstract 291).
7. Kodama Y, Hitotsumachi H, Shibata Y, Suzuki T, Sakuragi M, Kitade M et al. TAS-116, a novel, orally bioavailable highly potent hsp90 α /β selective inhibitor demonstrates favorable tissue distribution properties which lead to minimized ocular toxicity. Eur J Cancer 2012; 48: 89 (abstract 290).
8. Cheung WC, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia 2001; 15: 264-271.
9. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003; 63: 6174-6177.
10. Zhang L, Fok JH, Davies FE. Heat shock proteins in multiple myeloma. Oncotarget 2014; 5: 1132-1148.
11. Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K et al. Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 2009; 113: 5228-5236.
12. Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, Gonzalez D et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 2010; 24: 1804-1807.
13. Obeng EA, Carlson LM, Gutman DM, Harrington WJJr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916.
14. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046-1052.
15. Wu WC, Wu MH, Chang YC, Hsieh MC, Wu HJ, Cheng KC et al. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells. Exp Eye Res 2010; 91: 211-219.